Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 6/20 | 0.39 |
| ▸ | AXL | P30530 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11920297 | 0.94 | BRD4 (0.40) | BRD4METAXLHTTNCOA3 | |
| SCHEMBL2235855 | 0.93 | HTT (0.39) | BRD4METAXLHTTNCOA3 | |
| SCHEMBL2235271 | 0.92 | MAT2A (0.43) | BRD4METAXLHTTNCOA3 | |
| SCHEMBL2233232 | 0.91 | HTT (0.37) | BRD4METAXLHTTNCOA3 | |
| SCHEMBL2235092 | 0.90 | HTT (0.39) | BRD4METHTTNCOA3CDK1 | |
| SCHEMBL2236085 | 0.89 | HTT (0.39) | METAXLHTTNCOA3CDK1 | |
| SCHEMBL2235223 | 0.88 | NCOA3 (0.38) | HTTNCOA3CDK1 | |
| SCHEMBL2233418 | 0.88 | HTT (0.41) | METAXLHTTNCOA3CDK1 | |
| SCHEMBL2234582 | 0.86 | MAPK14 (0.43) | BRD4METMAPK14NPBWR1MCHR1 | |
| SCHEMBL4256906 | 0.85 | BRD4 (0.40) | BRD4METAXLMAPK14NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | claimed |
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | claimed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | claimed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | claimed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | GPR174, GPR17, PTGFR | BRD4 2607/4885MET 560/4885AXL 661/4885 |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | GPR174, GPR17, PTGFR | BRD4 2607/4885MET 560/4885AXL 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.